# An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score

> **NCT07554469** · — · NOT_YET_RECRUITING · sponsor: **Bayer** · enrollment: 500 (estimated)

## Conditions studied

- Chronic Kidney Disease
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Finerenone (Kerendia, BAY94-8862)

## Key facts

- **NCT ID:** NCT07554469
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2029-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07554469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07554469, "An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07554469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*